Autopsy report · NCT04522466

Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients

“Stop of the study by competent authority (ANSM)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 2 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Sponsor type

University, hospital or other

Conditions

Sars-CoV2

Interventions

Hydroxychloroquine (HCQ)

Participants

7

Sites

4

Countries

France

Trials that died the same way

• How Can a Driving Virtual Reality Tool Improve Quality of Life and Social Autonomy in Patients With Schizophrenia
  “Decision to stop the study” (65% match in meaning)
• A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
  “Business decision to stop the study.” (62% match in meaning)
• Naltrexone Treatment for Prolonged Grief Disorder (PGD)
  “We are terminating the study due to low accrual.” (61% match in meaning)
• Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)
  “Study stopped following management decision” (58% match in meaning)
• Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer
  “Study stopped due to low accrual.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.